GlassScriptPhysician profile
Daniel Villarosa
NPI 1578666129
$2,574.25
in general payments reported to CMS, 2019-2025
29 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $355 · 2021: $119 · 2022: $454 · 2023: $523 · 2024: $161 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.02 | 2019-2023 | Qulipta, Ubrelvy, Lo Loestrin Fe |
| Novo Nordisk INC | $235.15 | 2020-2023 | Wegovy |
| Pfizer INC. | $189.68 | 2020-2023 | |
| Lupin INC. | $132.20 | 2019 | |
| Biogen, INC. | $120.00 | 2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $119.87 | 2022 | |
| Covidien LP | $102.68 | 2019-2020 | |
| Myovant Sciences INC. | $96.66 | 2021-2022 | |
| Sage Therapeutics, LLC | $85.08 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $83.63 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $82.61 | 2019 | |
| Averitas Pharma INC. | $70.00 | 2023 | Qutenza |
| Collegium Pharmaceutical, INC. | $63.77 | 2023 | Belbuca |
| Lilly USA, LLC | $62.89 | 2024 | Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.35 | 2024-2025 | Jada System |
| Merck Sharp & Dohme LLC | $39.13 | 2019-2020 | |
| Coopersurgical, INC. | $38.18 | 2019-2022 | |
| Therapeuticsmd, INC. | $33.10 | 2019-2020 | |
| Roche Diagnostics Corporation | $28.02 | 2019 | |
| Aspira Women'S Health INC | $24.46 | 2024 | Ova1 |
| Evofem Biosciences, INC. | $20.79 | 2022 | |
| Exeltis, USA INC. | $20.68 | 2023 | Slynd |
| Sumitomo Pharma America, INC. | $20.58 | 2023 | Myfembree |
| Minerva Surgical, INC | $20.05 | 2019 | |
| Baxter Healthcare | $17.51 | 2024 | Perclot |
| Hologic Sales and Service, LLC | $16.88 | 2023 | Aptima |
| Allergan, INC. | $15.71 | 2019 | |
| Becton, Dickinson and Company | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Villarosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.